Company: PTHS
Filing Date: 2025-09-16
Form Type: 8-K/A
Source: 0001753926-25-001500
Chunk: 119

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-16
Form: 8-K/A
Chunk 119
---
 encourage their initial or continued service on our board of directors. Our board of directors is evaluating the adoption of a policy concerning the timing of such awards relative to material non-public information disclosures. We have not adopted any practice of timing, and do not time, the release of material non-public information to affect the value of equity awards granted to named executive officers or directors.

During the year ended December 31, 2024, there were no equity grants made to our executive officers during any period beginning four business days before the filing of a periodic report or current report disclosing material non-public information and ending one business day after the filing or furnishing of such report with the SEC.

<div align='center'>Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</div>

Market Information

Our Common Stock trades on NYSE American under the symbol “PTHS.”

Holders of our Common Stock

As of September 15, 2025, there were approximately
18 holders of record of our Common Stock. This number does not include shares of Common Stock held by brokerage clearing houses,
depositories or others in unregistered form.

Dividends

We have never declared or paid cash dividends
on our capital stock. We currently intend to retain all available funds and any future earnings for use in the operation of our
business and do not anticipate paying any dividends on our Common Stock in the foreseeable future. Any future determination to
declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating
results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.

Securities Authorized for Issuance under Equity Compensation Plans

Reference is made to “Executive and
Director Compensation—Equity Incentive Plan—The Pelthos Therapeutics Inc. Amended and Restated 2023 Equity Incentive
Plan” of this Form 8-K/A.

Recent Sales of Unregistered Securities

In conjunction with the consummation of
the Merger, the Company closed the PIPE Financing pursuant to the Securities Purchase Agreement executed concurrently with the
Merger Agreement, by and among the Company, and the PIPE Investors. At the closing of the PIPE Financing, which occurred immediately
prior to the Effective Time, the Company issued an aggregate of 50,100 shares of Series A Preferred Stock to the PIPE Investors
for gross proceeds of approximately $50.1 million, consisting of approximately $50.0 million in cash and